General Therapeutics, Inc.


Developer of non-viral RNA delivery technologies focused on ionizable lipid chemistry and lipid nanoparticle (LNP) formulations for in vitro and in vivo research. Offers ready-to-use LNP transfection kits, custom formulation and manufacturing services, and licensing for proprietary ionizable lipids. Reports preclinical performance data showing increased protein expression and reduced inflammatory/reactogenic responses relative to traditional LNPs.

Industries

N/A

General Therapeutics, Inc.


Products

Ready-to-use LNP transfection kits (multiple organ-targeting variants)

Pre-formulated LNP kits intended for rapid RNA encapsulation and delivery in both in vitro and in vivo experiments. Variants are formulated for general use and for targeting liver, spleen, lung, and hard-to-transfect cells.


Services

Custom LNP formulation and consultation

Project-specific formulation development, expert consultation, and guidance to select or optimize LNP compositions for research needs.

Large-scale lipid manufacturing and licensing

Provision of large-scale production of proprietary ionizable lipids and licensing arrangements for lipid chemistries.

Validation and performance testing support

Support for preclinical validation, including assay guidance and benchmarking in cell and animal models.

Expertise Areas

  • Non-viral RNA delivery
  • Lipid nanoparticle (LNP) formulation
  • Ionizable lipid chemistry
  • Preclinical in vitro and in vivo transfection
  • Show More (4)

Key Technologies

  • Ionizable lipid chemistry
  • Lipid nanoparticle (LNP) formulation
  • Non-SORT organ targeting
  • mRNA/siRNA/saRNA encapsulation
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.